The Annual General Meeting of
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---minutes-of-the-annual-general-meeting,c3968951
https://mb.cision.com/Public/20422/3968951/a69a03ca450e0ded.pdf
(c) 2024 Cision. All rights reserved., source